Bio-Rad Receives Frost & Sullivan 2012 North American Laboratory Researchers’ Choice: Future Market Leader of Digital PCR Technology Award

Date: 
2013-03-12
Frost & Sullivan Best Practices Award

Hercules, CA — March 12, 2013 — Bio-Rad Laboratories, Inc. today announced that it has received the Frost & Sullivan 2012 North American Laboratory Researchers’ Choice: Future Market Leader of Digital PCR Technology Award, for its QX100™ Droplet Digital™ PCR system. This annual award is given to a company that has demonstrated excellence and distinguished itself through proactive strategies that position the company as an industry leader.

In a study titled 2012 Quantitative and Digital PCR Instrumentation and Consumables Purchasing Trends, the global growth consulting company Frost & Sullivan reported that 56% of healthcare-related laboratory decision makers in North America said they plan to install the QX100 Droplet Digital PCR system in their labs within the next 12 months. This product choice is significantly higher than for any other digital PCR system, positioning the QX100 system as a potential future leader in the digital PCR market segment.

“The high sensitivity of digital PCR makes it ideal for a growing number of applications, including copy number variation, rare mutation detection, and absolute quantification of nucleic acid sequences,” said Frost & Sullivan research analyst Karolina Olszewska. “In this high-growth, promising market, we believe Bio-Rad’s investment in digital PCR will prove to be fruitful and they will be a future leader in this market segment.”

Droplet Digital PCR Shows Promise in Diagnostics and Personalized Medicine
Digital PCR is generating increasing attention in the industry for its potential in diagnostic and pharmaceutical applications. Researchers at Sangamo BioSciences have been using the QX100 system to develop therapies and potentially a cure for HIV.

“The QX100 system allowed us to easily, accurately, and reproducibly measure low-copy events in genomic DNA,” said Dr. Gary Lee, senior scientist at Sangamo BioSciences. “We have been able to demonstrate that it is the technology of choice when it comes to rare event detection applications, particularly in clinical studies.”

Researchers in the Ji Laboratory at Stanford University have also observed the benefits of the QX100 system. This group uses the system to accurately and precisely measure cancer genome amplifications in archival cancer tissue samples. Their work targeting these amplified oncogenes could ultimately lead to personalized therapies for cancer treatment.

Frost & Sullivan expects the U.S. dPCR instrumentation market to grow 52% from 2011 to 2016. They believe the QX100 system will emerge as a leader in the digital PCR platform on the market due to the system’s precision, simple workflow, and affordability.

Bio-Rad will be honored with this recognition at Frost & Sullivan’s 2012 Excellence in Best Practices Awards Banquet on March 12. The event recognizes companies, strategies, processes, and executives that have achieved world-class performance within their industries.

For more information about Bio-Rad’s QX100 Droplet Digital PCR system visit http://bit.ly/ddPCR_QX100.

About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation, and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages 50 years of experience in partnering with Global 1000 companies, emerging businesses, and the investment community from more than 40 offices on six continents. To join our Growth Partnership, please visit http://www.frost.com.

About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) has been at the center of scientific discovery for more than 60 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. The company is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 100,000 research and industry customers worldwide through its global network of operations. The company employs over 7,300 people globally and had revenues exceeding $2 billion in 2012. For more information, visit www.bio-rad.com.

This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, “believe,” “expect,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the “Risk Factors” in the Company’s public reports filed with the Securities and Exchange Commission, including the Company’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements.

For more information contact: 
Viresh Patel
Bio-Rad Laboratories, Inc.
925-474-8602
viresh_patel@bio-rad.com

Ken Li
Chempetitive Group
312-997-2436 x 112
kli@chempetitive.com